Stock 1521 FRONTAGE HOLDINGS CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Financials Frontage Holdings Corporation

Equities

1521

KYG3679P1019

Biotechnology & Medical Research

Market Closed - Hong Kong S.E.
Other stock markets
 04:08:20 2024-04-26 am EDT 		5-day change 1st Jan Change
1.28 HKD -1.54% Intraday chart for Frontage Holdings Corporation -2.29% -44.83%
Apr. 01 Frontage Holdings' Net Profit Plunges 59% in 2023 MT
Mar. 28 Frontage Holdings Corporation Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 1,139 1,117 1,039 756.2 603.5 330.8 - -
Enterprise Value (EV) 1 931.9 905.3 894.7 717.6 631.8 423.6 416.8 403.4
P/E ratio 61.7 x 66.2 x 58.2 x 30.2 x 57.1 x 19.6 x 12.9 x 14.4 x
Yield - - - - - - - -
Capitalization / Revenue 11.3 x 8.88 x 5.64 x 3.02 x 2.32 x 1.11 x 0.96 x 0.81 x
EV / Revenue 9.28 x 7.2 x 4.85 x 2.87 x 2.43 x 1.42 x 1.21 x 0.98 x
EV / EBITDA 36.7 x 38.1 x 20.6 x 13.1 x 10 x 7.51 x 6.33 x 6.08 x
EV / FCF 160 x 54.7 x -14.2 x 48.6 x - 14.9 x 14.5 x -98.2 x
FCF Yield 0.63% 1.83% -7.03% 2.06% - 6.7% 6.92% -1.02%
Price to Book 4.3 x 3.89 x 3.25 x 2.29 x 1.76 x 0.92 x 0.88 x 0.84 x
Nbr of stocks (in thousands) 2,007,641 2,033,549 2,051,280 2,036,428 2,031,318 2,022,832 - -
Reference price 2 0.5674 0.5495 0.5067 0.3713 0.2971 0.1635 0.1635 0.1635
Announcement Date 3/30/20 3/29/21 3/28/22 3/28/23 3/28/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 100.4 125.8 184.4 250.4 259.9 298.4 345.9 410.3
EBITDA 1 25.36 23.77 43.51 54.66 63.2 56.39 65.86 66.38
EBIT 1 21.07 15.75 25.83 33.68 19.63 28.45 37.96 45.05
Operating Margin 20.99% 12.52% 14% 13.45% 7.55% 9.53% 10.98% 10.98%
Earnings before Tax (EBT) 1 20.86 19.52 25.07 36.1 14.58 24.37 34.11 41.69
Net income 1 18.42 17.15 18.43 25.74 10.81 17.89 25.19 30.8
Net margin 18.35% 13.63% 9.99% 10.28% 4.16% 6% 7.28% 7.51%
EPS 2 0.009200 0.008300 0.008700 0.0123 0.005200 0.008360 0.0127 0.0114
Free Cash Flow 1 5.833 16.55 -62.89 14.78 - 28.37 28.85 -4.108
FCF margin 5.81% 13.16% -34.1% 5.9% - 9.51% 8.34% -1%
FCF Conversion (EBITDA) 23% 69.65% - 27.04% - 50.32% 43.8% -
FCF Conversion (Net income) 31.66% 96.52% - 57.42% - 158.6% 114.52% -
Dividend per Share 2 - - - - - - - -
Announcement Date 3/30/20 3/29/21 3/28/22 3/28/23 3/28/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2019 S2 2020 S1 2020 S2 2021 S1 2021 S2 2022 S1 2022 S2 2023 S1 2023 S2
Net sales 1 50.73 50.66 75.15 85.12 99.32 118.9 131.4 128.4 131.5
EBITDA - - - - - - - - -
EBIT 1 - - - 12.01 13.82 17.54 16.14 8.98 10.65
Operating Margin - - - 14.1% 13.92% 14.75% 12.28% 7% 8.1%
Earnings before Tax (EBT) - - - - - - - - -
Net income - - - - - - - - -
Net margin - - - - - - - - -
EPS 2 - - - 0.004200 0.004500 0.006100 0.006200 0.002200 0.003000
Dividend per Share - - - - - - - - -
Announcement Date 3/30/20 8/28/20 3/29/21 8/25/21 3/28/22 8/25/22 3/28/23 8/25/23 3/28/24
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - 28.3 92.9 86.1 72.6
Net Cash position 1 207 212 145 38.6 - - - -
Leverage (Debt/EBITDA) - - - - 0.447 x 1.647 x 1.307 x 1.094 x
Free Cash Flow 1 5.83 16.6 -62.9 14.8 - 28.4 28.8 -4.11
ROE (net income / shareholders' equity) 12% 6.21% 6.06% 7.88% 3.2% 5.5% 6.29% 7.51%
ROA (Net income/ Total Assets) 9.38% 4.93% 4.29% 5.01% 1.93% 3.24% 3.95% 4.64%
Assets 1 196.4 347.7 429.3 513.2 561.2 551.5 638.5 663.3
Book Value Per Share 2 0.1300 0.1400 0.1600 0.1600 0.1700 0.1800 0.1900 0.2000
Cash Flow per Share 2 0.0100 0.0200 0.0200 0.0300 0.0200 0.0200 0.0200 0.0300
Capex 1 13.9 15.1 50.6 47.7 - 36.3 38.4 41.3
Capex / Sales 13.84% 12% 27.43% 19.04% - 12.15% 11.09% 10.05%
Announcement Date 3/30/20 3/29/21 3/28/22 3/28/23 3/28/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Frontage Holdings Corporation

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
0.1635 USD
Average target price
0.2178 USD
Spread / Average Target
+33.22%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
FRONTAGE HOLDINGS CORPORATION Stock Frontage Holdings Corporation
-44.83% 331M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. 1521 Stock
  4. Financials Frontage Holdings Corporation